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Abstract
Background: Human menopausal gonadotrophins and recombinant human follicle stimulating hormone are the
two main gonadotrophin products utilized for controlled ovarian stimulation in assisted reproductive technologies.
In this meta-analysis, the number of oocytes was designated as the most relevant endpoint directly resulting from
ovarian stimulation, and therefore where the drug effect may be estimated with the best sensitivity.
Methods: All published randomized controlled trials on ovarian stimulation comparing the two gonadotrophin
products were evaluated. Internal validity was determined using Chalmers’ validated scale. If trials did not meet the
established quality criteria, a sensitivity analysis assessed the stability of the results. The comparison of continuous
variables was conducted following the weighted mean difference and the standardized mean difference (Cohen’s
effect size) with the random model. Given the known relationship of baseline conditions on treatment endpoints,
results were adjusted for age, body mass index and type of infertility.
Results: Sixteen studies involving 4040 patients were included. Treatment with human menopausal
gonadotrophins resulted in fewer oocytes (-1.54; 95% CI: -2.53 to -0.56; P < 0.0001) compared to recombinant
human follicle-stimulating hormone. When adjusting for baseline conditions, the mean difference estimate was
-2.10 (95% CI: -2.83 to -1.36; P < 0.001). A higher total dose of human menopausal gonadotrophin was necessary
(mean difference, 235.46 IU [95% CI: 16.62 to 454.30; P = 0.03]; standardized mean difference, 0.33 [95% CI: 0.08 to
0.58; P = 0.01]). The pregnancy absolute risk difference (RD [hMG-r-hFSH]) for fresh transfers was 3% (P = 0.051),
and the relative risk 1.10 (P = 0.06). When adjusted for baseline conditions, the relative risk was 1.04 (P = 0.49) and
absolute difference was 0.01 (P = 0.34), respectively.
Conclusions: Because baseline conditions are predictive of outcome, meta-analytic results are more sensitive when
these variables are considered. Using an endpoint closely associated with the stimulation period, sufficient
sensitivity is achieved to compare gonadotrophin treatments. As the largest meta-analysis published to date on
this subject, treatment with human menopausal gonadotrophins is characterized by fewer oocytes and a higher
total dose. When considering only fresh transfers, pregnancy rates were similar.
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Gonadotrophin products utilized in ovarian stimulation
are derived from urinary or recombinant sources. Urin-
ary products include human menopausal gonadotro-
phins (hMG, highly purified [HP-hMG]), urinary follicle
stimulating hormone (u-FSH) and human chorionic
gonadotrophin (hCG). The recombinant gonadotrophin
products are recombinant human follicle stimulating
hormone (r-hFSH), recombinant human luteinizing hor-
mone (r-hLH) and recombinant human chorionic gona-
dotrophin (r-hCG).
r-hFSH and hMG are two of the gonadotrophin pro-
ducts primarily used for controlled ovarian stimulation
(COS) in Assisted Reproduction Techniques (ART),
including in vitro fertilization (IVF) and intracytoplasmic
sperm injection (ICSI). Although both hMG and r-hFSH
have been shown to be effective, a number of studies have
further compared their safety and clinical effectiveness
[1-6]. r-hFSH is free from urinary protein contaminants,
with less immunogenic potential than the urinary-derived
medication, and ap r i o r imay be preferable from a safety
standpoint [7-9]. However, the question regarding whether
r-hFSH is preferred from the clinical perspective is the
topic of ongoing debate [10-12].
In terms of its primary constituents, hMG contains
both FSH and LH activity (in the form of LH and hCG,
which have short- and long half-lives, respectively).
According to the prevailing hypotheses, the beneficial
effect of exogenous LH activity in the form of hCG may
result in differences in embryo quality and endometrial
receptivity, providing higher live birth rates than r-hFSH
in women undergoing ovarian stimulation for ART uti-
lizing a long gonadotrophin-releasing hormone agonist
(GnRH-a) protocol [1,2]. In contrast, other authors have
reported better COS outcomes with r-hFSH in terms of
a lower total r-hFSH dose compared with urine-derived
gonadotrophins, and an increased number of follicles,
oocytes, embryos and/or pregnancies [3-6].
The comparison of hMG and r-hFSH has been evalu-
ated in various randomized controlled trials (RCTs),
retrospective studies, and meta-analyses. In their meta-
analysis published in 2003, Al-Inany compared r-hFSH
with urine-derived FSH products (hMG, purified FSH
[FSH-P] and highly purified FSH [FSH-HP]) in IVF/ICSI
cycles using a long GnRH-a protocol [13]. In four of the
studies identified, the comparison of hMG (n = 603
cycles) versus r-hFSH (n = 611 cycles) was limited to
clinical pregnancy per started cycle, with no significant
difference found between the two treatments (odds ratio
[OR] 0.81; 95% confidence interval [CI]: 0.63 to 1.05;
P = 0.11) [14-17].
W e s t e r g a a r dc o m p a r e dh M Ga n dr - h F S Hu s i n gt h e
same studies as Al-Inany, and added four other trials
[18-22]. No differences were found for ongoing preg-
nancy or live birth per woman (OR 1.27; 95% CI: 0.98
to 1.64), however borderline significance was observed
for some secondary outcomes in favour of both hMG
and r-hFSH depending on the endpoint. In 2005, Al-
I n a n yu p d a t e dt h e i r2 0 0 3s u b - g r o u pa n a l y s i so ff o u r
RCTs using the long protocol, adding two new studies
for a total of 686 patients treated with hMG and 678
treated with r-hFSH [23-25]. The pregnancy rate was
higher with hMG (OR 1.27; 95% CI: 1.00 to 1.62).
Including only twelve trials from a selection of twenty-
one potentially eligible RCTs, Al-Inany and colleagues
published a third meta-analysis in 2008 [26]. To the
meta-analysis published in 2005, five additional trials
were added totaling 1453 hMG cycles and 1484 r-hFSH
cycles; live birth rate was selected as the primary out-
come [5,22,26-29]. A significantly higher live birth rate
was found for hMG (OR 1.2; 95% CI: 1.01 to 1.42; P =
0.04) while ovarian hyperstimulation syndrome [OHSS]
rates were not significantly different (OR 1.21; 95% CI:
0.78 to 1.86; P = 0.39).
In their 2008 publication, Coomarasamy updated prior
reviews, identifying fifteen relevant RCTs using the long
GnRH-a protocol, but selecting only seven as meeting
the eligibility criteria for the review [5,14-17,24,25,30].
For the primary endpoint, live birth per woman rando-
mized, a significant increase was found in favour of
hMG (relative risk [RR] 1.18; 95% CI: 1.02 to 1.38; P =
0.03). Reconsidering their 2008 analysis, Al-Inany and
colleagues re-evaluated a subset of studies in their 2009
publication, with the aim of determining if the method
of fertilization might influence the outcomes of patients
receiving HP-hMG or r-hFSH [31]. Based on the subset
of six studies and 2371 patients, the ongoing pregnancy/
live birth rate did not differ significantly but demon-
strated borderline significance for improvement with
HP-hMG (OR 1.19; 95% CI: 0.98 to 1.44; P =0 . 0 8 )
[5,14,25,27,28,32]. However, in IVF cycles this difference
was significantly higher in favour of HP-hMG (OR 1.31;
95% CI: 1.02 to 1.68; P = 0.03) although not so for ICSI
cycles (OR 0.98; 95% CI: 0.70 to 1.36; P = 0.89).
The results from these meta-analyses present an
impression of heterogeneity and point to important
issues related to the most appropriate endpoint and the
difficulty in aggregating studies. As to the former point,
it is our position that the initial analytic approach
should focus on the number of oocytes retrieved in each
treatment group, because this is the primary goal and
direct result of ovarian stimulation and it is an endpoint
that is common to all ART studies. Although the live
birth rate constitutes the ultimate clinical endpoint of
ART, it is influenced by many variables in addition to
ovarian stimulation. Notably, many clinical decisions
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oocyte retrieval phase, in particular during the periods
of embryo culture and development, the embryo transfer
procedure and the luteal phase immediately thereafter.
Notwithstanding, many authors designated ongoing
pregnancy or live birth rates as the primary endpoint,
assuming that post-randomization decisions were
equally affecting the two treatment groups. Indeed, it is
well known that oocyte and embryo quality influence
the likelihood of achieving an ongoing pregnancy
[33,34].
Regarding the latter point on the challenges of aggre-
gating data from RCTs, it is critical to note that many
of the trials were designed with a specific statistical plan
and power, to demonstrate superiority, non-inferiority
or failed to state these details, thereby potentially contri-
buting to the aforementioned post-randomization varia-
bility. The influence of the clinician is further
pronounced at each phase, since dose modifications,
method of fertilization (conventional IVF or ICSI), and
other clinical decisions may be dictated by baseline vari-
ables such as patient age, antral follicle count or day 3
serum FSH levels [33]. In spite of strict patient eligibility
criteria, these factors may constitute a limitation for
meta-analyses based on literature reports (MAL), where
baseline demographics are only summarized for each
treatment group. Undoubtedly, significant heterogeneity
exists between studies; therefore using an assumption of
“fixed treatment” appears a priori unrealistic. Indeed, as
evident in the brief review above of prior meta-analyses
published in this field, use of different selection criteria
(e.g. studies that use long GnRH-a down-regulation,
GnRH-a flare protocol or GnRH antagonist) yield differ-
ent results even when a similar endpoint is utilized (e.g.
ongoing pregnancy or live birth rate).
With all these considerations in mind, the objective of
the current systematic review and meta-analysis was to
update the comparison between hMG and r-hFSH,
focusing on the number of oocytes retrieved and consid-
ering the potential impact of baseline variables. In parti-
cular, we reviewed previously published meta-analyses,
examining the differences in selection and exclusion of
studies, and the comparison of results. Additionally, we
included recently published RCTs comparing hMG and
r-hFSH.
Methods
Identification of literature
All publications related to RCTs comparing COS with
hMG and r-hFSH were identified using the Cochrane
Library’s Cochrane Menstrual Disorders and Subfertility
Review Group specialized register of controlled trials
(from January 1995 to August 2009) and the Cochrane
Central Register of Controlled Trials (from January 1998
to December 2009) as well as MEDLINE (from January
1966 to December 2009) and EMBASE (from January
2000 to December 2009) databases using the following
key words and/or medical subject heading (MeSH) ter-
minology: follicle stimulating hormone, FSH, r-hFSH,
hMG, recombinant human luteinizing hormone, recom-
binant hCG, OHSS, randomized controlled trial, con-
trolled clinical. Pharmaceutical manufacturers of fertility
medications were contacted to identify additional
unpublished and ongoing trials meeting the search
criteria.
Study selection and review methods
Prospective randomized or quasi-randomized controlled
trials (assimilated to randomization but not strictly ran-
domized, such as attributing treatment according to age)
comparing hMG and r-hFSH for COS in both IVF and
ICSI were included, irrespective of use of GnRH ago-
nists or antagonists. Studies that included patients with
polycystic ovarian syndrome (PCOS) were excluded
from the main analysis, although they were included in
the sensitivity analyses.
The selection of studies for inclusion in the review
and data extraction were undertaken by two reviewers
( D .E z c u r r a ,E .V a r l a n ) ,w i t hd i s a g r e e m e n t sr e s o l v e db y
a third reviewer (F. Contard). Where published reports
contained insufficient information, the authors were
contacted for additional details which were used to
make a decision about the trial’s eligibility for inclusion.
The methodological quality of unpublished reports and
publications of trials was evaluated for both the quality
of the trial and the details reported. The intrinsic quality
of each study report was assessed using a validated scale
that scores multiple aspects of the trial’s experimental
design, including sample size, randomization methods,
methods to preserve blinding, selection and withdrawal
criteria, outcome criteria, and statistical analysis; the
scoring range was from 0 to 100 [35].
Assessment of internal validity was performed using
the validated scale developed by Chalmers which judges
appropriateness of randomization and double blinding
and a description of dropouts and withdrawals by inter-
vention group [35]. The full publications and the struc-
tured abstracts of the clinical trials not identified in the
previous systematic reviews, masked as to authors,
affiliation, sources of trial support, and journal of publi-
cation were distributed to three reviewers (D. Ezcurra,
E. Varlan, F. Contard) for quality assessment. The arith-
metic mean of the Chalmers Score was calculated and
when values with differences greater than 30 were
observed, consensus was reached by the reviewers.
There were no major disagreements between the
reviewers. Only data from unpublished or published
reports of trials with an acceptable quality (Chalmers
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were eliminated by quality criteria, a sensitivity analysis
was used to assess the stability of the results.
All the studies according to the aforementioned cri-
teria were included, without restriction of language,
published in peer-reviewed journals, or as meeting
abstracts, or unpublished. We evaluated all reports with
these conditions; however, our selection of reports was
limited to those for which enough accuracy was pro-
vided on methodology.
Statistical analysis
The primary objective of the current analysis was to
compare gonadotrophin treatments administered during
the period of ovarian stimulation. Accordingly, we
selected the number of oocytes as the primary endpoint,
an outcome directly following the COS period, as the
most appropriate measure, since this is the point of
least influence by the clinician in an RCT. Furthermore,
the number of oocytes is the most common result
reported in the trials. Secondary endpoints were also
considered, including the total dose of gonadotrophins,
clinical pregnancy rate (CPR), OHSS, and live birth rate
when documented in the publication.
The number of oocytes was considered to follow a
pattern of normal distribution. Differences over all the
studies were pooled and weighted by the inverse of their
variance (weighted mean difference method). For binary
variables (OHSS or CPR), we estimated the relative risk
(RR) and the absolute risk difference (RD) to estimate
the number needed to treat (NNT), since these two sta-
tistics are considered more clinically intuitive than odds
ratios [36]. The comparison of continuous variables
(number of oocytes, gonadotrophin dosage) was con-
ducted following both the weighted mean difference and
the standardized mean difference (Cohen’s effect size).
As the number of trials was limited, and had unequal
sample sizes, we systematically used the random effects
model, which is much more adaptable as shown in
Brockwell [37]. The fixed effects model was used only
for sensitivity purposes.
Due to the analytic approach employed, our meta-ana-
lysis favoured the inclusion of a maximum number of
studies, excluding only studies for which internal validity
was considered weak or insufficiently documented. Evi-
dence of superiority of one treatment was accepted
when the results of the main analysis and the sensitivity
analyses were consistent.
Consideration of baseline factors
Consistent research has de m o n s t r a t e dt h a tA R To u t -
comes, particularly end-stage pregnancy endpoints, are
strongly affected by certain baseline conditions [38-40].
Individual patient data was not available for our analysis
however known factors predictive of number of oocytes
and CPR were used in an attempt to adjust for these con-
ditions. Among literature published on predictive factors,
Howles and colleagues examined factors related to the
number of oocytes and identified age, basal FSH, body
mass index (BMI), and number of follicles as the determi-
nant predictors from a pool of 1378 patients [38]. For
pregnancy rates, Lintsen and colleagues provided evidence
of the key factors of age and cause of infertility, in particu-
lar primary infertility [39]. While a majority of the trials
reported non-significant differences of baseline demo-
graphics, some trials noted significant differences. The
absence of a significant difference in baseline variables in a
small trial does not rule out the potential impact of even a
slight imbalance of these factors on treatment outcomes.
Therefore an adjustment for baseline correction was per-
formed by correcting the observed value of the tested drug
by its estimated marginal value (EMV) at the baseline con-
ditions for the control treatment.
For continuous variables, by designating y as the pri-
mary endpoint, x1,..xk as the baseline predictors, and a0,
a1,..ak estimated by a general linear model, the prediction
model found in the literature and the estimated marginal
mean (EMM) Yg of the tested drug for baseline condi-
tions determined by the control statement g1,..gk are:
(1) Y = a0 + ∑ ai xi; and
(2) Yg =a 0 + ∑ ai gI; thus
(3) from (1) and (2), Yg =Y+∑ ai (xi - gi) [41].
For binary variables like CPR, the same calculation
was based on logarithmic transformations, where the ai
is the estimated log (hazard ratios):
(1) Log(Y) = a0 + ∑ ai xi; and
(2) Log(Yg)=a 0+ ∑ ai gI; thus
(3) from (1) and (2), Yg = Y exp (∑ ai (xi - gi)).
For the number of oocytes, age and BMI were consid-
ered as the predictive factors according to Howles [38].
However other variables such as number of follicles
were not documented in the literature and therefore
were not included in our analysis. For age and BMI, the
coefficients aage = 0.21 and abmi = 0.17 were used. More-
over, when age was reported as the proportion of
women > 35 years, we used aage = 1.5 in using the dif-
ference of the proportions. When evaluating CPR, age,
primary infertility and male factor infertility were used
as the predictive factors according to Lintsen, et al. [39].
For age and infertility, the estimated hazard ratios (HR),
HRage = 0.95/year and HRinf = 0.9 were used. Moreover,
when age was reported as the proportion of women > 35
years, aage = 0.5 was used for the difference of the propor-
tions. For variables not available in between-group
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assumed; however, the study was weighted inversely pro-
portional to the number of documented baseline
conditions.
Given the expected high number of patients and to
preserve balance of both types of possible statistical
errors, a P value of < 0.01 was considered to be signifi-
cant. For statistical calculations, RevMan (Release 5.0.22,
Cochrane Collaboration, Oxford, UK) and SAS 9.1 (SAS
Institute, Inc, Cary, NC USA) were used.
Results
Main study list and sensitivity analyses
From 30 publications comparing r-hFSH versus hMG in
ART, seven were meta-analyses/reviews (Al-Inany [2003,
2005, 2008, 2009], Westergaard, Coomarasamy, Afnan),
four were excluded as duplicate publications (Plateau
[2004, 2008], Smitz, Ziebe) and three studies were
excluded because of insufficient details (Elwin [unpub-
lished data], Loutradis, Strowitski) [1,2,13,18,23,
26,30-32,42-45]. The 16 remaining studies which were
truly or quasi-randomized met the inclusion criteria and
were found to be of acceptable internal validity
[5,14-17,19-22,24,25,27-29,46,47]. Two studies were
reported only via congress abstracts (Ruvolo, Serhal)
while 14 studies were published as peer-reviewed papers.
A total of 4040 patients were analysed in this meta-analy-
sis, and the primary characteristics of the included stu-
dies are summarized in Table 1.
The main analysis was based on all 16 studies (Table 1).
The sensitivity analysis was carried out on two other
selections: sub-group 1 was comprised of 15 studies,
excluding Strehler as the study population included
patients with polycystic ovarian syndrome (PCOS); and
sub-group 2 consisted of 14 studies excluding those
described by abstracts only (Serhal and Ruvolo)
[21,22,47]. The effect size was estimated on the main
analysis, however, a significant difference in favour of
one of the two treatments was considered only when
all three analyses were significant at the two-sided
level of significance (P = 0.01). Pregnancy data was
included by all authors; however, not all reports distin-
guished between clinical PR and live birth rate. For the
included studies, the reported infertility diagnoses were
tubal disease, male factor infertility, endometriosis and
unexplained infertility, however, Ng restricted the indi-
cation for ART to male factor infertility only in their
comparison between groups; that is, no specific female
diagnosis was included [16].
Women over 40 years old were specifically excluded in
the 16 trials. The mean age was documented per treat-
ment arm, and although no differences were significant,
some trials (in particular smaller trials) were found to
have slightly different ages. In 14 out of 16 studies, the
proportion of patients with primary infertility was docu-
mented (or retrieved), ranging from 40% to 90%. The
demographics of the two treatment groups matched rea-
sonably well across the 16 studies, except for Strehler’s
where a significant difference in the mean number
(± standard deviation [SD]) of previous cycles was
observed (hMG, 0.77 [0.91] versus r-hFSH, 1.15 [0.93],
P < 0.001) [22]. Importantly, the authors suspected that
the comparison of the two treatments might be influ-
enced by this difference.
Of the 16 included studies, 13 utilized a long GnRH
agonist protocol, while three studies did not [19,22,27].
Although a significant effect may be expected due to
use of a GnRH agonist short protocol, oral contraceptive
pill pre-treatment and/or a GnRH antagonist, such an
effect was not found, likely due to lack of statistical
power (data not reported).
Risk of bias in included studies
An attempt to quantify the risk of bias was undertaken
by assigning the Chalmers score, where the individual
aspects of the trials’ methods were aggregated (Table 2).
We found an acceptable value for all the trials (Chal-
mers > 50), although the trials were not of the same
quality, and particular concerns were noted during the
scoring process, resulting in lower final scores. Trials
used randomization lists or were quasi-randomized and
concealment of allocation was detailed in most of the
studies. No marked differences were found in compari-
son of baseline demographic data, in spite of visible
small differences in categories such as cause of infertility
or patient age, in particular with the smaller studies. In
all the studies, the selection did not exactly reflect the
intent-to-treat population, in particular, not all patients
recruited and entering the studies were documented and
analysed. As studies differed in other medications pro-
vided during the trials, potential influence of these
adjunct medications in the larger studies may have
influenced the results. Only a few of the reports men-
tioned the statistical power being tested, but it was pos-
sible to calculate the power a posteriori.
Other sources of potential bias were also noted. Wes-
tergaard’s 2001 publication did not provide actual data
on any baseline conditions, stating only that the treat-
ment groups were comparable [17]. The fact that there
was no significant difference between treatment arms,
particularly for small (n < 100) studies likely reflects the
challenges encountered with a type-II error associated
with an under-powered study. Dosage was response-dri-
ven for 13 of 16 trials with Balasch, Kilani and Duijkers
as the exceptions, since a fixed dose was primarily used
in their studies [24,25,46]. Consequently, these trials
were not included in the estimation of total gonadotro-
phin dosage.
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First author,
year,
reference
number
Methods Patient population Interventions Chalmers
Score
Duijkers 1997
[46]
RCT, allocation method not
specified
Female patients with tubal pathology or
unexplained infertility, ages 20 to 40 years
GnRH-a for 14 days then HMG versus
r-hFSH 150 IU daily
58
Jansen et al.
1998 [19]
RCT, assessor-blind; allocation by
number from randomization list
that corresponded to medication
box
Normo-ovulatory females, ages 18 to 39
years; excluded endocrine-related causes,
including PCOS, and male infertility
HMG versus r-hFSH 150-225 IU daily
for 4 days then adjusted
72
Kornilov et al.
1999 [20]
RCT, allocation by randomization
method not provided
Female patients undergoing IVF GnRH-a long protocol then hMG
versus r-hFSH 150-300 IU daily for
5 days then adjusted
67
Serhal et al.
2000 [21]
Pseudo-randomised, open-label,
single-centre study. Allocation by
alternating weeks.
Couples with infertility due to tubal factor
or unexplained, endometriosis and male
factor infertility allowed, female age < 40
(mean 34, SD 4.4) yrs, BMI < 30
GnRH-a long protocol then hMG
versus r-hFSH 150-300 IU daily for
5 days then adjusted
60
Ng et al. 2001
[16]
RCT, allocation by computerized
randomization in sealed
envelopes
Normo-ovulatory females, age < 40 years;
severe male factor requiring ICSI
GnRH-a long protocol then hMG
versus r-hFSH 300 IU for first 2 days,
then 150 IU daily
56
Strehler et al.
2001 [22]
RCT, allocation by computerized
randomization
Unselected female population that did not
specifically exclude PCOS, age ≤ 40 years.
GnRH-a short protocol then hMG
versus r-hFSH 150-450 IU daily
67
Westergaard
et al. 2001
[17]
RCT, allocation by computerized
randomization
Normo-ovulatory females, age < 40 years;
excluded endocrine-related causes,
including PCOS
GnRH-a long protocol then hMG
versus r-hFSH 225 IU daily for 7 days
then adjusted
64
Gordon et al.
2001 [15]
RCT, assessor-blinded; allocation
by computerized randomization
Normo-ovulatory females, ages 20 to 39
years; excluded endocrine-related causes,
including PCOS, and male infertility
GnRH-a long protocol then hMG
versus r-hFSH 225 IU daily for 5 days
then adjusted
63
European and
Israeli Study
Group 2002
[14]
RCT, allocation by computerized
randomization list in blocks of
four
Normo-ovulatory females, ages 18-38 years;
excluded endocrine disorders, including
PCOS
GnRH-a long protocol then hMG
versus r-hFSH 225 IU daily for 5 days
then adjusted
71
Kilani et al.
2003 [25]
RCT, allocation by randomization
sequence
Normo-ovulatory females with no PCOS or
endometriosis
GnRH-a long protocol then hMG
versus r-hFSH 150 IU daily for 14 days
then adjusted
67
Balasch et al.
2003 [24]
RCT, allocation by computerized
randomization
Normo-ovulatory females, ages 26-37 years
with no PCOS
GnRH-a long protocol then hMG
versus r-hFSH 150 IU daily for 14 days
then adjusted
65
Rashidi et al.
2005 [29]
RCT, allocation by computerized
randomization
Normo-ovulatory females, ages ≤ 35 years
with no PCOS or endometriosis
GnRH-a long protocol then hMG
versus r-hFSH 150 IU daily then
adjusted
72
Andersen
et al. 2006 [5]
RCT, allocation by computerized
randomization, stratified by
patient age (< 35 years, 35-37
years)
Normo-ovulatory females, ages 21-37 years;
excluded PCOS, endometriosis stage III/IV,
severe male factor requiring ICSI
GnRH-a long protocol then hMG
versus r-hFSH 225 IU daily for 5 days
then adjusted
77
Hompes et al.
2008 [28]
RCT, allocation by permuted
blocks of random size
Unselected female population, ages 18-39
years, excluding endocrine abnormality
including PCOS
GnRH-a long protocol then hMG
versus r-hFSH 150 IU daily fixed dose
with adjustment permitted
76
Bosch et al.
2008 [27]
RCT, allocation by computerized
allocation
Normo-ovulatory females, ages 18-37 years,
excluding PCOS
OCP pre-treatment then hMG versus r-
hFSH 225 IU daily for 2 days, then
adjusted; fixed GnRH-ant protocol
beginning cycle day 6
57
Ruvolo et al.
2009 [47]
RCT, allocation by computerized
allocation
Unselected IVF female population whit FSH
level of < 12 IU/mL and BMI < 28 kg/m
2
GnRH-a long protocol then hMG
versus r-hFSH 225 IU daily fixed dose
with adjustment permitted
52
RCT = randomized controlled trial; hMG = human menopausal gonadotrophins; r-hFSH = recombinant human follicle-stimulating hormone; PCOS = polycystic
ovarian syndrome; GnRH-a = gonadotrophin releasing hormone agonist; IVF = in vitro fertilization; ICSI = intracytoplasmic sperm injection.
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When considering the main analysis of all 16 studies
(data reported by authors for 3952 patients), signifi-
cantly fewer oocytes were retrieved in the hMG treat-
ment arm (mean 9.4 ± 6.3) compared with the r-hFSH
group (mean 10.9 ± 6.6) (Figure 1 and Table 3). The
mean difference was -1.54 (95% CI: -2.53 to -0.56; P <
0.0001) using the random model (Figure 1), and -1.74
(95% CI: -2.12 to -1.35; P < 0.0001) using the fixed
model (Table 3, main analysis [fixed model]), with sig-
nificant heterogeneity observed among the studies (I
2 =
63%, P = 0.0004). When adjusting the mean values for
baseline conditions, we found a mean difference estimate
of -2.10 (95% CI: -2.83 to -1.36; P < 0.001) (Table 3).
Table 2 Current and prior meta-analyses comparing hMG versus r-hFSH
Al-In,
2003
Al-In,
2005
Al-In,
2008
Al-In,
2009
Coom
2008
West,
2003
Sponsor Paper Chalmers nhMG nr-hFSH
Duijkers, 1997 [46] 0 0 0 0 0 0 0 1 58 7 6
Jansen et al. 1998 [19] 0 1 1 0 0 1 1 1 72 35 54
Kornilov et al. 1999 [20] 0 0 0 0 0 1 0 1 67 40 28
Serhal et al. 2000 [21] 0 0 0 0 0 1 0 0 60 144 94
Ng et al. 2001 [16] 1 1 1 0 1 1 0 1 56 20 20
Strehler et al. 2001 [22] 0 1 1 0 0 1 0 1 67 248 259
Westergaard et al. 2001 [17] 1 1 1 0 1 1 1 1 64 189 190
Gordon et al. 2001 [15] 1 1 1 0 1 1 0 1 63 29 39
European and Israeli Study Group
2002 [14]
1 1 1 1 1 1 1 1 71 357 336
Kilani et al. 2003 [25] 0 1 1 1 1 0 1 1 67 50 50
Balasch et al. 2003 [24] 0 1 1 0 1 0 1 1 65 25 25
Rashidi et al. 2005 [29] 0 0 1 0 0 0 0 1 72 30 30
Andersen et al. 2006 [5] 0 0 1 1 1 0 1 1 77 363 368
Hompes et al. 2008 [28] 0 0 1 1 0 0 1 1 76 312 317
Bosch et al. 2008 [27] 0 0 1 1 0 0 1 1 57 122 126
Ruvolo et al. 2009 [47] 0 0 0 0 0 0 0 0 52 10 19
16 studies identified from the literature search, compared with previous meta-analyses. The first 6 columns compared the referenced meta-analyses using the
following definitions: sponsor, whether or not the study was funded by a pharmaceutical company; paper, whether a peer-reviewed publication or abstract only
was available; Chalmers, the Chalmers internal validity mean score [29]. The last two columns are the sample sizes for each study.
Figure 1 Number of oocytes. Number of oocytes for hMG versus r-hFSH in 16 studies (main analysis population, data reported by study
authors for 3952 patients). Forest tree with mean difference using the random effects model. hMG = human menopausal gonadotrophins; r-
hFSH = recombinant human follicle-stimulating hormone; EISG = The European and Israeli Study Group; SD = standard deviation; CI =
confidence interval.
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Page 7 of 12Several secondary analyses were conducted (Table 3): a
sensitivity analysis was conducted on the two aforemen-
tioned subsets, sub-group 1 and sub-group 2. Over all
the alternative analyses, the mean difference varied
between -1.54 and -2.10, and the difference was always
highly significant (P < 0.001, results not shown).
Total gonadotrophin dose
As shown in Figure 2 and Table 3, a higher total dose of
hMG was used with a MD for hMG versus r-hFSH of
235.46 IU (95% CI: 16.61 to 454.30; P = 0.03) and a
SMD of 0.33 (95% CI: 0.08 to 0.58; P = 0.01]. Further-
more, we estimated the ratio of number of oocytes/1000
IU of gonadotrophin dose to be 4.39 and 5.10 for hMG
and r-hFSH, respectively, with a mean difference of 0.70
oocytes/1000 IU (95% CI: 0.10 to 1.30; P = 0.021).
Pregnancy rates
Figure 3 and Table 4 present the findings of the preg-
nancy rates analysis for hMG versus r-hFSH. The abso-
lute risk difference (RD) for hMG minus r-hFSH was
0.03 (95% CI: -0.01 to 0.07; P = 0.051) and a relative
risk (RR) was found of 1.10 (95% CI: 0.97 to 1.25; P =
0.06). There were few indices of heterogeneity thus the
effect appears homogeneous among all the studies (P =
0.99). When adjusting for baseline conditions, the RR
for hMG versus r-hFSH was 1.04 (95% CI: 0.89 to 1.15;
P = 0.49) and an absolute RD was 0.01 (95% CI: -0.02 to
0.04; P = 0.34). Pregnancy rates were also estimated and
compared in the alternative selections (sub-groups 1
and 2) for sensitivity purposes by using the relative risk
(RR) and the absolute risk difference (RD) (Table 4).
The difference between the two treatments was not sig-
nificant in any of the comparisons undertaken.
OHSS rates
OHSS rates were similar between the two groups, with-
out any significant differences in the main analysis as
well as for the sub-group results (Table 4).
Discussion
Methodological considerations
Combined with sensitivity analyses, our method of trial
selection provided a robust number of studies (n = 16)
Table 3 Number of oocytes and total gonadotrophin dose for hMG versus r-hFSH
Studied endpoint for hMG versus r-hFSH MD 95% CI p value SDM 95% CI P value
Number of oocytes
- Main analysis -1.54 -2.53, -0.56 < 0.0001 -0.23 -0.36, -0.10 < 0.0001
- Sub-group 1 -1.68 -2.69, -0.68 < 0.0001 -0.25 -0.38, -0.12 < 0.0001
- Sub-group 2 -1.57 -2.65, -0.49 < 0.001 -0.24 -0.38, -0.11 < 0.0001
- Main analysis (fixed model) -1.74 -2.12, -1.35 < 0.0001 -0.26 -0.32, -0.19 < 0.0001
Number of oocytes adjusted for baseline -2.10 -2.83, -1.36 < 0.001 -0.35 -0.47, -0.22 < 0.0001
Dosage (IU) 235.46 16.62, 454.30 0.03 0.33 0.08, 0.58 0.01
hMG = human menopausal gonadotrophins; r-hFSH = recombinant human follicle-stimulating hormone; MD = mean difference; SDM = standardized mean
difference.
Figure 2 Total gonadotrophin dose. Total gonadotrophins dose for hMG versus r-hFSH in 14 studies (data reported by study authors for 3272
patients). Forest tree with mean difference using the random effects model. Results from Balasch, Kilani and Duijkers are not included, since a
fixed dose was used in their studies [24,25,46]. hMG = human menopausal gonadotrophins; r-hFSH = recombinant human follicle-stimulating
hormone; EISG = The European and Israeli Study Group; CI = confidence interval.
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Page 8 of 12compared to prior meta-analyses which included
between 4 and 12 studies comparing hMG and r-hFSH
[13,18,23,26,30,31]. As a result of the large sample size
of this meta-analysis, and the fact that several endpoints
were considered, the level of significance was set at P <
0.01. Although the random model of meta-analysis is
considered more conservative it is also much more rea-
listic. It has been shown by Brockwell that for studies of
unequal sample sizes or for a small number of studies,
the random model is the preferred analytic method [37].
For both pregnancy rate and number of oocytes, the
prediction models of Howles and Lintsen found the
coefficient of determination larger than R
2 =0 . 1 0 ,w h e n
considering baseline variables such as age, reasons for
infertility, and BMI [38,39]. Compared with these deter-
minations, the effect size observed between the two
drugs is negligible (< 0.01). It follows that in an RCT
comparing the two drugs, baseline conditions may have
a higher effect than treatment itself. A direct conse-
quence is that comparison between these drugs without
adjustment for baseline variables can be noticeably inac-
curate and biased, depending on inevitable differences at
baseline. Although a baseline comparison fails to show
statistically significant differences, a discrepancy may
exist which may affect the treatment outcome; this is
particularly true for small trials. As a result of adjusting
for baseline variables when comparing the two treat-
ments in our analysis, the impact of these variables was
Figure 3 Pregnancy rate. Pregnancy rate for hMG versus r-hFSH in 16 studies (main analysis population, data reported by study authors for
4040 patients). Forest tree with random model and relative risk. hMG = human menopausal gonadotrophins; r-hFSH = recombinant human
follicle-stimulating hormone; EISG = The European and Israeli Study Group; CI = confidence interval.
Table 4 Pregnancy rate and OHSS rate for hMG versus r-hFSH
Studied endpoint for hMG versus r-hFSH RR 95% CI p value RD 95% CI P value
Pregnancy rate
- Main analysis 1.10 0.97, 1.25 0.06 0.03 -0.01, 0.07 0.051
- Sub-group 1 1.09 0.95, 1.24 0.10 0.03 -0.01, 0.07 0.08
- Sub-group 2 1.09 0.95, 1.26 0.12 0.03 -0.01, 0.07 0.08
Pregnancy rate adjusted for baseline 1.04 0.89, 1.15 0.49 0.01 -0.02, 0.04 0.34
OHSS
- Main analysis 1.47 0.91, 2.39 0.12 0.02 -0.00, 0.04 0.72
- Sub-group 1 1.40 0.84, 2.36 0.20 0.01 -0.00, 0.03 0.65
- Sub-group 2 1.40 0.84, 2.34 0.20 0.01 -0.00, 0.03 0.62
hMG = human menopausal gonadotrophins; r-hFSH = recombinant human follicle-stimulating hormone; OHSS = ovarian hyperstimulation syndrome;
RR = relative risk; RD = absolute risk difference.
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Page 9 of 12reduced when considering the oocyte and pregnancy
rate endpoints. Age, BMI and infertility rates were used
in this study, as these were the only variables consis-
tently reported across the majority of studies. Our
attempt to adjust for baseline parameters has evident
limitations, but provides a very important correction in
the context of meta-analyses conducted from literature
research (MAL). Obviously differences in baseline condi-
tions may be more evident in smaller studies, but the
weight of a small study may remain important and bias
the results. From this perspective, we believe that (1)
the simple assertion that baseline characteristics are
similar between treatment groups is not sufficient evi-
dence to conclude that the treatment groups are truly
matched; (2) that more baseline conditions should be
routinely reported and systematically analysed; and (3)
that treatment comparisons should be routinely and sys-
tematically adjusted for key baseline parameters.
The effect of post-randomization clinical actions
In the majority of ART studies considered in this meta-
analysis, only gonadotrophin treatment during the COS
period was randomized. All other decisions made by the
physician or embryologist were non-randomized and
were center-specific and/or patient-specific. As with
baseline conditions, these post-randomization actions
are expected to have a key impact on ART endpoints
otherwise a patient-specific approach to treatment
would not be undertaken. In this context, a “distant”
endpoint such as pregnancy is most likely influenced by
these actions. The number of retrieved oocytes repre-
sents the first evaluable endpoint immediately following
the COS timeframe, and thus the impact of post-rando-
mization interventions is minimal, compared with more
“distant” endpoints. Although not conclusive evidence of
post-randomization effects, the highly significant differ-
ence (P < 0.001 for both baseline adjusted and unad-
justed estimates) found for the number of oocytes
compared with the lack of significance (P =0 . 0 6a n d
P = 0.49 for unadjusted and adjusted baseline estimates,
respectively) found for the pregnancy rate suggests that
the number of oocytes is less influenced by post-rando-
mization factors thus representing smaller uncontrolled
variability and a more sensitive estimate of the differ-
ence between the two treatments.
Comparison with earlier findings
Number of oocytes and total gonadotrophin dose
The findings of the present meta-analysis are in agree-
ment with previous meta-analyses regarding the number
of oocytes, consistently found to be higher for r-hFSH
in almost all the studies and all the meta-analyses. The
estimate of effect size (-0.35, 95% CI: -0.47 to -0.22) is
smaller compared with Al-Inany’s findings (0.80, 95%
CI: 0.56 to 1.05) [26]. We also agree with earlier reports
on the total doses (IU) administered. Al-Inany estimated
a lower total dose administered of -282.5 IU (95% CI:
-311 to -254) for r-hFSH compared with hMG; we
found a very similar value of 235.46 IU (95% CI: 16.62
to 454.30), equivalent to slightly more than three 75 IU
vial equivalents [26]. Thus, our estimates confirm the
higher dose administered in the hMG group, although
the difference was not statistically significant. Further
supporting the overall finding, the number of oocytes/
1000 IU total gonadotrophin dose was 4.39 and 5.10 for
hMG and r-hFSH, respectively.
Pregnancy rate
On the basis of the 16 studies, no significant difference
for pregnancy rate was found between the two treat-
ments (P =0 . 0 6a n dP = 0.49 for baseline unadjusted
and adjusted estimates, respectively). Even following
adjustment for baseline conditions, the final estimate of
risk difference was 0.01 (P =0 . 4 9 )f o rh M Gv e r s u s
r-hFSH. Based on this finding, it seems that providing
estimates in terms of odds ratios may be confusing for
clinicians. In particular when the studied proportion is
much higher than zero, the odds ratio will always be
much higher than the relative risk. Accordingly, an odds
ratio of 1.20 in fact corresponds to a relative risk of 1.09
or an absolute risk difference of 0.03. Moreover, our
estimated risk difference of 0.01 found by baseline
adjustment is equivalent to a number needed to treat
(which assesses treatment benefit) approximately equal
to 100 which may be considered as a negligible value
with which to reach a conclusive decision regarding the
two treatments. Given the difficulty to reach a definitive
conclusion on pregnancy rate when only fresh transfers
are included, and considering the significant difference
found for the number of oocytes retrieved, the most
relevant pregnancy endpoint may be the cumulative
pregnancy rate, which combines the outcomes of
embryos generated from the same COS cycle, with fresh
and frozen thawed transfers.
In terms of number of oocytes retrieved and total
gonadotrophin dose, the differences between the two
treatments is significant, whereas this is not the case for
the pregnancy rate. These findings may be attributed to
the difference between the two treatments (r-hFSH and
hMG) as well as heterogeneity between the studies
themselves. Thus, for the number of oocytes and total
gonadotrophin dose, the difference between the two
treatments is favourable for r-hFSH, however, a signifi-
cant variance was found in the results between the indi-
vidual studies. In contrast, the pregnancy rate is almost
the same among treatment groups and the between-
study variation for this difference is minimal. One rea-
son for this difference is purely statistical, in which the
number of oocytes and total gonadotrophin dose are
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Page 10 of 12counts for which the standard deviations are often pro-
portional to the mean and are much greater than in the
case of the pregnancy rate where the proportions are
close to one. Additionally, the number of transferred
embryos was similar between studies.
Further, the apparent absence of heterogeneity of effi-
cacy for the two treatments may be attributed to the
much smaller contribution of r-hFSH versus hMG in
terms of pregnancy rate, where post-randomization vari-
ables have a greater impact on treatment outcome.
Indeed, the homogeneity of the difference between r-
hFSH and hMG may be regarded as additional evidence
of the difficulty in observing such an effect since the
drug administered is one of many interventions that
ultimately impact the treatment outcome. In contrast,
the number of oocytes and total gonadotrophin dose are
variables with a more causal effect with the studied
treatments as their impact is assessed directly during or
immediately following the stimulation period. In this
regard, the effect of the gonadotrophin is important,
thus significant differences may be expected.
Conclusion
As the largest meta-analysis published on the comparison
of hMG and r-hFSH for COS, based on 4040 patients in
16 RCTs, hMG produced fewer oocytes and required a
higher total gonadotrophin dose compared to r-hFSH.
Pregnancy rates were found to be similar, in contrast to
the conclusion of several prior meta-analyses [26,30].
Baseline conditions are known to determine treatment
outcome, perhaps to the same extent as treatment inter-
ventions. Accordingly, a limitation of the present meta-
analysis which is inherent to all MAL meta-analyses in
which individual patient data is not available, is the
approximation of the influence of baseline conditions
and post-randomization procedures. Consequently, due
to the limitations of MAL meta-analyses, sensitivity is
improved after adjustment for baseline variables, and a
comparison based on “distant” endpoints such as the
pregnancy rate is of limited value due to the substantial
influence of post-randomization procedures. In this
regard, only endpoints as close as possible of the end of
the COS period appear to have sufficient sensitivity to
compare stimulation treatments. A meta-analysis based
on individual patient data would enhance the sensitivity
of these results.
Finally, due to the small variance observed with the
two treatments during COS compared with the influen-
tial effect of baseline conditions and post-randomization
procedures, it remains to be clarified whether evidence
collected from meta-analyses confined to RCTs may be
complimented by retrospective analyses representing a
more comprehensive level of treatment experience. In
these conditions, it is probably better to increase the
sample size by using large databases since the randomi-
zation is limited to the COS drugs, which represent a
small portion of the entire treatment intervention and
therefore dilute the findings of “gold standard evidence”
obtained from RCTs. As this was not the aim of the
current analysis, further examination of this perspective
is warranted.
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